Aponil 100 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

aponil 100 mg tabletes

medochemie ltd., cyprus - nimesulīds - tablete - 100 mg

Dapril 20 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

dapril 20 mg tabletes

medochemie ltd., cyprus - lizinoprils - tablete - 20 mg

Dapril 10 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

dapril 10 mg tabletes

medochemie ltd., cyprus - lizinoprils - tablete - 10 mg

Dapril 5 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

dapril 5 mg tabletes

medochemie ltd., cyprus - lizinoprils - tablete - 5 mg

Sevoflurane Piramal 100% inhalācijas tvaiki, šķidrums Latvija - latviešu - Zāļu valsts aģentūra

sevoflurane piramal 100% inhalācijas tvaiki, šķidrums

piramal critical care b.v., netherlands - sevoflurāns - inhalācijas tvaiki, šķidrums - 100%

Uplizna Eiropas Savienība - latviešu - EMA (European Medicines Agency)

uplizna

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - imūnsupresanti - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.

Ultomiris Eiropas Savienība - latviešu - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - hemoglobīnūrija, paroksizmāla - selective immunosuppressants - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Enspryng Eiropas Savienība - latviešu - EMA (European Medicines Agency)

enspryng

roche registration gmbh - satralizumab - neuromyelitis optica - imūnsupresanti - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Cilvēka albumīns BTS 50 g/l šķīdums infūzijām Latvija - latviešu - Zāļu valsts aģentūra

cilvēka albumīns bts 50 g/l šķīdums infūzijām

baltijas terapeitiskais serviss, sia, latvia - albumīns, cilvēka - Šķīdums infūzijām - 50 g/l

Avodart 0,5 mg mīkstās kapsulas Latvija - latviešu - Zāļu valsts aģentūra

avodart 0,5 mg mīkstās kapsulas

glaxosmithkline (ireland) limited, ireland - dutasterīds - kapsula, mīkstā - 0,5 mg